Novocure Reports Promising Tumor Treating Fields Therapy Study for Brain Metastases

Key Points:

• Novocure stock surged 6.3% higher today after positive study results on Tumor Treating Fields therapy.
• Patients receiving TTFields therapy had a median time to intracranial progression of 21.9 months, showing significant improvement.
• However, key secondary endpoints like overall survival and neurocognitive failure were not achieved.

Conclusion:

Novocure's stock surge is fueled by promising Tumor Treating Fields therapy results, but challenges remain with unmet study endpoints.